Skip to main content
OpenTrials

Clinical trial condition

Exocrine Pancreatic Insufficiency

Explore clinical trials studying Exocrine Pancreatic Insufficiency. Study availability and eligibility vary by location and protocol.

105 public trials 14 recruiting studies
Refine in advanced search Browse all conditions

Exocrine Pancreatic Insufficiency trial results

Completed

Liprotamase Efficacy Trial in Patients With Cystic Fibrosis-Related Exocrine Pancreatic Insufficiency

NCT00449878

Conditions
Congenital, Hereditary, and Neonatal Diseases and Abnormalities, Cystic Fibrosis, Digestive System Diseases, +6 more
Locations
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician. Los Angeles, California, United States
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician. Stanford, California, United States
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician. Denver, Colorado, United States
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician. Jacksonville, Florida, United States
View all 29 locations
View Trial Details
Completed

Open-Label Phase III Long-Term Safety Trial of Liprotamase

NCT00449904

Conditions
Congenital, Hereditary, and Neonatal Diseases and Abnormalities, Cystic Fibrosis, Digestive System Diseases, +6 more
Locations
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician. Oakland, California, United States
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician. Denver, Colorado, United States
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician. Jacksonville, Florida, United States
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician. Miami, Florida, United States
View all 39 locations
View Trial Details
Completed

Oral TheraCLEC™ - Total in Cystic Fibrosis Subjects With Exocrine Pancreatic Insufficiency

NCT00095732

Conditions
Congenital, Hereditary, and Neonatal Diseases and Abnormalities, Cystic Fibrosis, Digestive System Diseases, +7 more
Locations
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician. Birmingham, Alabama, United States
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician. Palo Alto, California, United States
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician. Denver, Colorado, United States
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician. Gainesville, Florida, United States
View all 27 locations
View Trial Details
Completed

Evaluation of Safety and Tolerability of Creon Micro in Children Younger Than Four Years With Pancreatic Exocrine Insufficiency

NCT01747330

Conditions
Congenital, Hereditary, and Neonatal Diseases and Abnormalities, Cystic Fibrosis, Digestive System Diseases, +7 more
Locations
  • Site Reference ID/Investigator# 80716 Barnaul, Russia
  • Site Reference ID/Investigator# 80693 Moscow, Russia
  • Site Reference ID/Investigator# 80698 Novosibirsk, Russia
  • Site Reference ID/Investigator# 80713 Novosibirsk, Russia
View Trial Details
Completed

A Study of the Efficacy and Tolerability of Pancrelipase Microtablet (MT) Capsules for the Treatment of Cystic Fibrosis-dependent Exocrine Pancreatic Insufficiency

NCT00662675

Conditions
Congenital, Hereditary, and Neonatal Diseases and Abnormalities, Cystic Fibrosis, Digestive System Diseases, +12 more
Locations
  • Long Beach, California, United States
  • Los Angeles, California, United States
  • Orlando, Florida, United States
  • Louisville, Kentucky, United States
View Trial Details
Completed

Control of Steatorrhea in Participants With Cystic Fibrosis and Exocrine Pancreatic Insufficiency

NCT01327703

Conditions
Congenital, Hereditary, and Neonatal Diseases and Abnormalities, Cystic Fibrosis, Digestive System Diseases, +14 more
Locations
  • Klinikum-Bochum Bochum, Germany
  • Universitätsklinikum Carl Gustav Carus Dresden, Germany
  • Universitaetsklinikum Erlangen Erlangen, Germany
  • Jena University Hospital, Universitaetsklinikum Jena Jena, Germany
View all 13 locations
View Trial Details
Completed

A Study to Evaluate the Mode of Administration and Safety of EUR-1008 (APT-1008) in Infants 1 to 12 Months of Age

NCT01100606

Conditions
Congenital, Hereditary, and Neonatal Diseases and Abnormalities, Cystic Fibrosis, Digestive System Diseases, +6 more
Locations
  • Nemours Children's Clinic Jacksonville, Florida, United States
  • Children's Lung Specialists Ltd. Las Vegas, Nevada, United States
  • Akron Children's Hospital Akron, Ohio, United States
  • Cincinnati Children's Hospital Medical Center Cincinnati, Ohio, United States
View Trial Details
Completed

Safety and Efficacy Study of 2 Pancreatic Enzymes for Treatment of Exocrine Pancreatic Insufficiency in Cystic Fibrosis.

NCT01641393

Conditions
Congenital, Hereditary, and Neonatal Diseases and Abnormalities, Cystic Fibrosis, Digestive System Diseases, +7 more
Locations
  • University Hospital Antwerp - Universitair Ziekenhuis Antwerpen (UZA) Antwerp, Belgium
  • Universitair Ziekenhuis Gent, Centrum voor Mucoviscidose Ghent, Belgium
  • Clinic of Paediatric Diseases at UMHAT Dr Georgi Stranski Pleven, Bulgaria
  • Clinic of Genetic and Paediatric Diseases at UMHAT Sveti Georgi Plovdiv, Bulgaria
View all 37 locations
View Trial Details
Completed

A Randomized, Double-Blind, Dose Response-Control, Crossover Study to Evaluate the Safety and Efficacy of Two Doses of EUR-1008 (APT-1008) in Chronic Pancreatitis (CP) Participants With Exocrine Pancreatic Insufficiency (EPI)

NCT00788593

Conditions
Chronic Disease, Chronic Pancreatitis, Digestive System Diseases, +7 more
Locations
  • Woodland International Research Group Little Rock, Arkansas, United States
  • HealthCare Partners Medical Group Los Angeles, California, United States
  • University of Florida, General Clinical Research Center Gainesville, Florida, United States
  • Advanced Medical Research Center Port Orange, Florida, United States
View all 18 locations
View Trial Details

Related conditions